BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28560603)

  • 1. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
    Okamoto K; Miyoshi K; Murawaki Y
    PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
    Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.
    Liu Y; Li Y; Wang R; Qin S; Liu J; Su F; Yang Y; Zhao F; Wang Z; Wu Q
    J Exp Clin Cancer Res; 2016 Jan; 35():19. PubMed ID: 26817584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
    Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
    BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated microRNA expression profiles in cholangiocarcinoma cell-derived exosomes.
    Kitdumrongthum S; Metheetrairut C; Charoensawan V; Ounjai P; Janpipatkul K; Panvongsa W; Weerachayaphorn J; Piyachaturawat P; Chairoungdua A
    Life Sci; 2018 Oct; 210():65-75. PubMed ID: 30165035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic significance of microRNA-203 in cholangiocarcinoma.
    Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
    Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
    Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Cell-Derived Extracellular Vesicles Promote the Growth, Metastasis and Chemoresistance in Cholangiocarcinoma by Delivering microRNA-210 to Downregulate RECK.
    Fu Y; Liu Y; Liu K; Tan L
    Mol Biotechnol; 2023 Jul; 65(7):1151-1164. PubMed ID: 36454533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA TM4SF1-AS1 predicts dismal outcomes and promotes cholangiocarcinoma progression via modulating miR-744-3p.
    Jiang H; Li W; Xue Z; Chen W; Zhao L; Song H; Hou J
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101915. PubMed ID: 35346892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
    Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
    Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
    Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.